We are determined to realize the
promise of precision medicine.
HI-Bio™ was founded on the idea that therapies for immune-mediated diseases (IMDs) have the potential to achieve better results for patients.
Many IMDs stem from the dysfunction of cells that make up the immune system, including plasma cells, neutrophils, mast cells and more. These cells are responsible for critical functions and processes. HI-Bio’s programs apply a precision medicine approach to target, modulate or deplete these cellular drivers of disease with therapeutics.
HI-Bio is applying a precision medicine approach. Now is the time for medicines that use genetic and immunological insights to transform the lives of patients with severe IMDs.
Travis Murdoch, M.D.Chief Executive Officer
Christina Carlson, J.D.General Counsel
Carl Henrik EnellChief Operating Officer
Uptal Patel, M.D.Chief Medical Officer
Michele AndersonSenior Vice President, Regulatory Affairs
Lorna DeanSenior Vice President, Development Operations
Leslie Chinn, Ph.D.Vice President, Clinical Pharmacology
Jaideep Dudani, Ph.D.Vice President, Portfolio Strategy and Management
Donna Flesher, Ph.D.Vice President, Biomarker and Bioanalytical Sciences
Houston Gilbert, Ph.D.Vice President, Biometrics
Gijsbert Grotenbreg, Ph.D.Vice President, Biology
Joyce LiawVice President, Finance
David Schisla, Ph.D.Vice President, Chemistry Manufacturing and Controls
Sunil Agarwal, M.D.Former Executive Vice President, Head of Development and Chief Medical Officer at Sana Biotechnology
Paul BernsChairman of the Board, HI-Bio and Managing Director at ARCH Venture Partners
Fred Cohen, M.D., D.Phil.Co-Founder and Chairman at Monograph Capital Partners
Chris DimitropoulosManaging Director of Healthcare Investments at Alpha Wave Global
Barbara Krebs-Pohl, Ph.D.Chief Business Officer at MorphoSys
Rachel Mears, J.D.Partner at Jeito Capital
Mark Murcko, Ph.D.Founding Chief Scientific Officer at Dewpoint Therapeutics and Relay Therapeutics
Travis Murdoch, M.D.Chief Executive Officer
Carol SuhPartner at ARCH Venture Partners
Matthew Albert, M.D., Ph.D.Former Senior Vice President, Biology & Translational Genetics at insitro
John Davis, M.D., M.P.H., M.S.Former Senior Vice President, Head of Early Clinical Development at Pfizer
Chris Goodnow, Ph.D.Executive Director of the Garvan Institute of Medical Research
Stefan Härtle, Ph.D.Head of Clinical Pharmacology at MorphoSys
Ariella Kelman, M.D.Chief Medical Officer, Biora Therapeutics
Brian Kotzin, M.D.Senior Vice President, Clinical Development and Head of Immunology at Nektar Therapeutics
John Lowe, M.D.Former Senior Director of Pathology at Genentech
Andrew Luster, M.D., Ph.D.Chief of the Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital
Gregg Silverman, M.D.Mamdouha S. Bobst Professor of Internal Medicine, Department of Medicine at NYU Langone Health
Contact Us
info@hibio.com